SMS text check-ins to track symptoms for people with plasma cell disorders

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational, non-interventional study from Mayo Clinic explores using everyday text message reminders to monitor symptoms in adults starting a new therapy for MM or AL amyloidosis. Researchers aim to see if this approach is feasible, acceptable, and capable of identifying symptoms early that may need clinical attention. The study does not assign a treatment but observes how patients respond to routine SMS monitoring during their care.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age \>= 18 years
* Diagnosis of MM or AL based on IMWG diagnostic criteria
* Planned to start a new treatment within 14 days (+/-7 days)
* Able to provide written informed consent

Exclusion Criteria:

* Not able to give informed consent

Where it's running

• Mayo Clinic in Rochester
  Rochester, Minnesota, United States Recruiting

Study contacts

• Principal investigator: Nadine H. Abdallah, MD — Mayo Clinic in Rochester
• Study coordinator: Clinical Trials Referral Office
• Email: mayocliniccancerstudies@mayo.edu
• Phone: 855-776-0015

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Tec Dara for newly diagnosed multiple myeloma with light chain amyloidosis

  This study tests whether tec listamab plus daratumumab can help newly diagnosed multiple myeloma with AL amyloidosis and whether the combination is safe.

  Recruiting Phase 2 Shanghai Zhongshan Hospital · Shanghai · NCT07638683

• How the IGLV1-44 light chain causes AL amyloidosis and POEMS

  This project tests whether specific IGLV1-44 light‑chain sequences drive AL amyloidosis and POEMS and whether nanobodies can recognize and stabilize those light chains in adults with AL amyloidosis, POEMS, or multiple myeloma.

  Recruiting Fondazione IRCCS Policlinico San Matteo di Pavia · Pavia · NCT07448935

• How N-glycosylation of light chains affects AL amyloidosis diagnosis and treatment

  This project will test whether a sugar modification called N-glycosylation on immunoglobulin light chains helps cause disease or changes how AL amyloidosis and related monoclonal gammopathies behave in adults.

  Recruiting Fondazione IRCCS Policlinico San Matteo di Pavia · Pavia, PV · NCT07448779

• Registry and sample resource for patients with plasma cell disorders

  This study is gathering information from patients with plasma cell disorders like multiple myeloma to see how to improve their treatment and quality of life.

  Recruiting Ohio State University Comprehensive Cancer Center · Columbus, Ohio · NCT01408225

• 6MW5311 in adults with relapsed or refractory blood cancers

  This study tests increasing doses of 6MW5311 in adults with multiple myeloma, AML, or CMML to see if it is safe and tolerable and to find a suitable dose for later studies.

  Recruiting Phase 1 Mabwell (Shanghai) Bioscience Co., Ltd. · Shanghai, Shanghai Municipality · NCT07914556

• Tailored exercise program to improve quality of life for adults with hematologic cancers

  This pilot trial tests a personalized 16-week exercise program to see if it’s feasible and helpful for adults with acute myeloid leukemia, lymphoma, or multiple myeloma after first-line treatment.

  Recruiting Gruppo Italiano Malattie EMatologiche dell'Adulto · Roma, Rm and 2 other locations · NCT07912684

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.